腺病毒介导BCSC-1基因实验性治疗鼻咽癌

目的探讨抑癌基因BCSC-1对肿瘤的治疗作用。方法制备重组腺病毒Ad5-BCSC-1。用CellTiter 96 A-queous细胞增殖单一溶液检测试剂盒检测细胞增殖。肿瘤体内注射Ad5-BCSC-1,以注射Ad5-egfp或PBS作为对照,1周后重复注射,再2周后处死小鼠,称瘤重。结果Ad5-BCSC-1感染的CNE-2L2细胞的生长明显减慢,细胞在培养中聚集成大细胞团块。注射PBS、Ad5-egfp和Ad5-BCSC-1的小鼠CNE-2L2肿瘤的平均瘤重分别为(2·28±0·73)、(2·07±0·40)和(0·58±0·32)g。Ad5-BCSC-1组显著低于PBS和Ad5-egfp组(P<0·05)。结论瘤体内注射Ad5-BCSC-1能抑制CNE-2L2肿瘤的生长,提示BCSC-1基因治疗对BCSC-1基因缺失或表达低下的肿瘤可能有治疗作用。

Experimental BCSC-1 gene therapy on nasopharyngeal carcinoma mediated by adenovirus

OBJECTIVE: To explore the therapeutic value of BCSC-1 in tumor gene therapy. METHODS: Recombinant adenovirus Ad5-BCSC-1 was prepared. Cell proliferation was assayed using CellTiter 96 Aqueous one solution cell proliferation assay kit. Ad5-BCSC-1 was injected into tumor with Ad5-egfp or with PBS injection as controls. The injections were repeated one weak later. After another 2 weeks, the mice were sacrificed and the tumors were excised and weighed. RESULTS: The growth of the CNE-2L2 cell infected with Ad5-BCSC-1 in vitro was remarkably slower than that of the controls, the wild type cell and the cell infected with Ad5-egfp. In contrast to the controls, the cells infected with Ad5-BCSC-1 aggregated and formed huge messes in the culture. The average weight of the CNE-2L2 tumors in mice was (2.28 +/- 0.73), (2.07 +/- 0.40), and (0.58 +/- 0.32) g for the tumors injected with PBS, Ad5-egfp, and Ad5-BCSC-1, respectively (Ad5-BCSC-1 vs. PBS or Ad5-egfp, P<0.05). CONCLUSION: Intra-tumor injection of Ad5-BCSC-1 can suppress the growth of CNE-2L2 tumor in nude mice, suggesting that BCSC-1 gene therapy may be effective for tumors with low or no expression of BCSC-1 gene.